NEW YORK, March 2 (GenomeWeb News) - George Mason University and the Instituto Superiore di Sanitá in Rome plan to develop a proteomics research program to discover new drug targets and biomarkers for early cancer detection, the organizations said yesterday.
The research will be led by center co-directors Lance Liotta and Emanuel Petricoin through the George Mason University's Center for Applied Proteomics and Molecular Medicine, the statement said.
The ISS, which is the main scientific arm of the Italian National Health Service, will provide Mason with human tissue and blood samples, funding for Italian and Mason scientists to work at the CAPMM laboratories, and access to research from a consortium of Italian cancer centers, the statement added.
Specific collaborative initiatives include nanotechnology development; identification of new bloodborne biomarkers for early detection of ovarian, colorectal, lung, and breast cancers; discovery of new drug targets for advanced stages of colorectal, lung, and breast cancers; and discovery of new drug targets for childhood leukemia, childhood cancers, and brain cancers, the partners said.
The agreement represents a continuation of a US National Cancer Institute project Liotta, Petricoin, and the ISS worked on to develop proteomics technologies for analysis of cancer and other diseases.